PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of ...( ANNAPOLIS Md. Feb. 8 /- PharmAthe...)

ANNAPOLIS, Md., Feb. 8 /PRNewswire-FirstCall/ -- PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it has appointed Joan Fusco, Ph.D. Senior Vice President of Operations.

Dr. Fusco brings more than twenty years of experience in the biotechnology and vaccines industry, with broad experience in a variety of functional areas including, R&D, pilot plant operations, regulatory affairs, clinical development and commercial manufacturing within both large and small biopharmaceutical companies. Prior to joining PharmAthene, Dr. Fusco served as Senior Vice President, Operations for Acambis, Inc., where she had been responsible for overall operations of the company, including development, manufacturing, quality systems, project management, IT and logistics/purchasing. While at Acambis, Dr. Fusco oversaw the development and manufacturing operations of the company's biodefense and portfolio programs, and was responsible for ensuring delivery of a newly-licensed biodefense vaccine. Prior thereto, Dr. Fusco served as Vice President, Technical Affairs - Vaccines, and Vice President, Global Project Management for Baxter Healthcare Corporation, BioScience Division, where she held project management responsibility for the vaccines development pipeline and successfully shepherded two new vaccines from discovery through to commercialization.

David P. Wright, President and Chief Executive Officer, commented, "Joan's considerable experience in biodefense product development and commercialization is a tremendous asset to PharmAthene. We're very pleased to welcome her to our senior management team and are confident that her expertise in all facets of biopharmaceutical product development will help to ensure the success of Valortim (TM) and Protexia(R), our biodefense product candidates intended for the treatment of anthrax and chemical nerve agents, respectively."

Mr. Wright co
'/>"/>